Verrica Pharmaceuticals 3Q26 Earnings Conference Call - VERRICA PHARMACEUTICALS INC

Explicit Guidance:

• Cash Runway: Assuming full utilization of the remaining $15 million borrowing commitment under the credit facility, cash runway is expected to extend beyond the key data readouts for the Common Warts program and into the fourth quarter of 2027.
• Revenue Expectations: For the fourth quarter 2026 and 2027, management expects Q4 seasonality to result in lower volume due to consumer patterns (fewer office hours) but anticipates sequential growth in net revenue driven by improved yield and physician adoption maturation.
• Operating Expenses: R&D expenses for the Common Warts Phase III program will remain non-cash (funded by Torrey Pharmaceutical) until their $40 million commitment is exhausted toward the program's end; future operating plans will include trial costs for the proposed Gorlin syndrome proof-of-concept study.

Business-Segment Outlook:

• Y-CAMP (Molluscum):
  • Commercial Strategy: Focus shifting from prescriber targeting to driving volume and yield by converting "dabblers" to loyalists and reducing prescription leakage.
  • Geographic Expansion: Commercializing in Israel via partner Madomi Pharma (exclusive agreement signed July 2026); pursuing global expansion opportunities with other partners due to the disease's prevalence across demographics.
  • Market Access: Optimizing pharmacy vs. medical benefit coverage; targeting a 95/5 split (currently 95 million lives covered under pharmacy, 137 million under medical) to improve yield by directing medical benefit claims into in-network pharmacies.
  • Growth Drivers (2027): Continued physician adoption, optimization of reimbursement channels, and educational efforts highlighting early treatment efficacy vs. "watch and wait" approaches.
  • Seasonality: Q4 2026 expected to show typical seasonal dips; 2027 anticipated to normalize and mature.
• Y-CAMP (Common Warts):
  • Pipeline Status: Phase III program includes two pivotal trials: COVE-2 (enrollment complete) and COBE-3 (>50% enrollment as of late August).
  • Data Readouts: Top-line data expected for COVE-2 in Q1 2027 and COBE-3 in mid-2027.
  • Commercial Potential: Label expansion could open a multi-billion dollar market (approx. 22 million U.S. patients); expected to leverage existing commercial infrastructure for synergies.
  • Regulatory Path: Management aims to submit regulatory filings as quickly as possible post-readout (no specific date confirmed), with a goal to accelerate the process given enrollment exceeded expectations.
• VP315 (Basal Cell Carcinoma):
  • Gorlin Syndrome: Exploring a proof-of-concept (POC) study (Phase IIb/Phase I extension) to evaluate efficacy in Gorlin syndrome patients. Protocol drafting and cost estimation are in progress; clinical supply is on hand.
  • Sporadic BCC: Proceeding with Phase III design aligned with FDA (two 100-patient placebo-controlled studies); POC data in Gorlin patients will inform the final Phase III protocol for sporadic BCC or potentially support a pivotal Gorlin-specific program.

Market and Competitive Outlook:

• Molluscum: Primary competitive challenge remains the "watch and wait" mindset; management believes new data showing 4x faster clearance and 3x higher complete clearance rates will drive earlier intervention and market shift.
• Common Warts: No FDA-approved prescription therapies currently exist; current standard of care (surgery) is viewed as inadequate (painful, scarring). High unmet need facilitates enrollment in placebo-controlled trials.
• Gorlin Syndrome: No FDA-approved therapies currently exist. Existing oral hedgehog inhibitors face tolerability issues (muscle cramps, hair loss, taste loss) limiting long-term use.
• Competitive Landscape (VP315): Anticipates a synergistic rather than purely competitive dynamic with emerging hedgehog inhibitors (prevention-focused); VP315 offers a lytic and immunologic effect (reducing existing lesions + potential abscopal effect).

Macro / Industry Outlook:

• Economy/Interest Rates: Interest expense decreased to $0.3 million (Q3 2026) from $2.1 million (prior year) due to settlement of the Orvimed debt facility; no significant FX or macro-economic headwinds impacting commercial outlook mentioned.
• Supply Chain: Collaboration with Torrey Pharmaceutical covers ~90% of Common Warts program costs; supply agreements for Japan launched; no supply disruptions anticipated.

Strategic Initiatives:

• Capital Raising: Unlocked remaining $15 million (total facility $27.5M) from credit facility (partnered with Chairman Paul Manning) upon meeting revenue/operational milestones; funds designated to complete Common Warts pivotal studies.
• Partnerships:
  • Torrey Pharmaceutical: Funding $40M of Common Warts Phase III costs; commercial supply agreement for Japan launch.
  • Madomi Pharma: Exclusive distribution/marketing/supply agreement for Israel.
• Product Development:
  • Y-CAMP Label Expansion: Pursuing approval for common warts; leveraging existing dermatology/pediatric distribution.
  • VP315 Indication Expansion: Designing POC study for Gorlin syndrome to evaluate abscopal effects and dosing strategies prior to or alongside sporadic BCC Phase III.
• Operational: Finalizing clinical protocols, budgets, and timelines for Gorlin study; utilizing existing manufactured clinical supply.

Risks and Headwinds to Outlook:

• Clinical Readiness: Success of Y-CAMP label expansion is contingent on achieving statistically significant improvement over vehicle in pivotal trials; failure to clear efficacy hurdles could delay regulatory submissions.
• Study Design: FDA feedback suggests including Gorlin patients in Phase III, but management prefers a POC study first to confirm efficacy before committing to a blinded Phase III in this population.
• Execution Risks: Commercial success relies on overcoming the "watch and wait" cultural barrier and successfully navigating pharmacy vs. medical benefit reimbursement pathways.
• Funding Dependency: Continued reliance on Torrey Pharmaceutical for R&D funding in Common Warts program; future financing needs for Gorlin study not yet fully quantified in operating plans.
• General: Standard risks associated with clinical development, regulatory approval, and commercial adoption; forward-looking statements are subject to uncertainties and risks detailed in SEC filings.

Management Tone on the Future:

• Confidence: Highly confident in Y-CAMP's commercial momentum (record revenue, improving yield) and clinical potential in Common Warts (enrollment ahead of schedule, strong interim data signals).
• Strategic Optimism: Enthusiastic about the multi-billion dollar opportunity in Common Warts and the potential for VP315 to transform care in Gorlin syndrome and BCC due to its unique mechanism and unmet need.
• Hedging: Cautious regarding specific Phase III readout dates for Gorlin/BCC, emphasizing a "data-driven" approach to protocol finalization; no specific revenue targets provided for new indications.

Miscellaneous:

• Financials Reference: Q3 2026 total revenue $6.9M (excl. $10M one-time milestone from 2025); Net Y-CAMP revenue $5.7M (+57.9% YoY); Gross margin 89.8%.
• Capital Structure: As of Sept 30, 2026, cash on hand $14.4M (including $12.5M drawn from credit facility).